Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to $2.1 million.

  • Dna X's Cash & Equivalents fell 7641.28% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 7641.28%. This contributed to the annual value of $5.3 million for FY2024, which is 4314.14% down from last year.
  • Dna X's Cash & Equivalents amounted to $2.1 million in Q3 2025, which was down 7641.28% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Dna X's Cash & Equivalents ranged from a high of $18.2 million in Q2 2022 and a low of $2.0 million during Q2 2025
  • For the 5-year period, Dna X's Cash & Equivalents averaged around $9.3 million, with its median value being $9.6 million (2024).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first crashed by 8188.22% in 2021, then soared by 16326.86% in 2022.
  • Over the past 5 years, Dna X's Cash & Equivalents (Quarter) stood at $11.2 million in 2021, then increased by 17.63% to $13.2 million in 2022, then dropped by 28.88% to $9.4 million in 2023, then plummeted by 43.14% to $5.3 million in 2024, then plummeted by 60.0% to $2.1 million in 2025.
  • Its Cash & Equivalents was $2.1 million in Q3 2025, compared to $2.0 million in Q2 2025 and $2.1 million in Q1 2025.